Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BJU Int ; 109 Suppl 3: 4, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22458481
2.
Urology ; 74(3): 535-9, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19604560

ABSTRACT

OBJECTIVES: To ascertain the potential utility of magnetic resonance imaging in providing additional clarification of those solid renal mass lesions identified at routine antenatal ultrasonography in early pregnancy and influencing the management of such lesions. METHODS: We present 7 patients in whom magnetic resonance imaging was used to diagnose, stage, and monitor renal lesions detected during pregnancy. RESULTS: Magnetic resonance imaging provided for improved imaging of renal mass lesions identified at antenatal ultrasonography, without the use of ionizing radiation, and permitted management determined by optimal radiographic assessment of such lesions without fetal irradiation. CONCLUSIONS: Magnetic resonance imaging is the most appropriate method to further investigate renal masses identified at routine antenatal ultrasonography early in pregnancy.


Subject(s)
Kidney Neoplasms/diagnosis , Magnetic Resonance Imaging , Pregnancy Complications, Neoplastic/diagnosis , Prenatal Diagnosis/methods , Adult , Female , Humans , Pregnancy
3.
BJU Int ; 96(4): 540-6, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16104907

ABSTRACT

OBJECTIVE: To assess renal tumours for hypoxic regions using 18F-fluoromisonidazole (18F-FMISO) positron emission tomography (PET), a recognized noninvasive method for detecting hypoxia in tumours, as renal cell carcinoma (RCC) can be potentially cured with nephrectomy but recurrence develops in most patients, who then respond poorly to treatments such as chemotherapy, and hypoxia is known to confer resistance to radiotherapy and chemotherapy in many solid tumours. PATIENTS AND METHODS: In all, 17 patients had 18F-FMISO PET scans before nephrectomy for presumed RCC. Specimens were examined histologically, and immunohistochemistry was used to compare the microvessel density (MVD) as an indicator of angiogenesis in the tumour and normal parenchyma, in 15 patients. Tumour oxygenation was measured invasively in three patients using a polarographic oxygen sensor probe. RESULTS: Of the 15 patients with histological results, 11 had RCC and four had other tumours. Although there was a trend there was no statistically significant (P = 0.14) difference in the maximum standardized uptake value (SUV(max)) when comparing the region of the kidney involved with RCC; the mean (95% confidence interval) SUV(max) in the tumours was 1.3 (0.15), whilst that in the normal contralateral kidney was 1.1 (0.22). The MVD was greater in RCC, at 13.7 (3.1) mean vessels per high-power field than in normal tissue, at 6.9 (1.9). Hypoxia as measured polarographically was detected in three RCCs (median pO2 9.6 mmHg) compared to normal parenchyma at 37.6 mmHg. CONCLUSIONS: Although 18F-FMISO scans showed significant uptake in other solid tumours, there was only mild 18F-FMISO uptake in the present RCCs. The invasive measurements indicated that there was hypoxia in RCC, but the median pO2 did not fall below 9.5 mmHg. Further direct studies of renal tumour oxygenation combined with therapies directed towards hypoxia may allow a better understanding of the relationship between 18F-FMISO results and the biological significance of hypoxia in RCC.


Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Hypoxia/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Misonidazole/analogs & derivatives , Positron-Emission Tomography , Radiopharmaceuticals , Adult , Aged , Carcinoma, Renal Cell/blood supply , Carcinoma, Renal Cell/chemistry , Female , Humans , Hypoxia/diagnosis , Immunohistochemistry , Kidney Neoplasms/blood supply , Kidney Neoplasms/chemistry , Male , Middle Aged , Neovascularization, Pathologic , Nephrectomy , Oxygen/analysis , Polarography/methods
SELECTION OF CITATIONS
SEARCH DETAIL